408 related articles for article (PubMed ID: 19766896)
1. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.
Verreth W; De Keyzer D; Davey PC; Geeraert B; Mertens A; Herregods MC; Smith G; Desjardins F; Balligand JL; Holvoet P
Br J Pharmacol; 2007 Jun; 151(3):347-55. PubMed ID: 17384667
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
4. [Effects of Tongxinluo and Simvastatin on the stabilization of vulnerable atherosclerotic plaques of aorta in aortic atherosclerosis and molecular mechanism thereof: a comparative study with rabbits].
Li Z; Yang YJ; Qin XW; Ruan YM; Chen X; Meng L; Zhang HD
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3146-50. PubMed ID: 17313769
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
7. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosenson RS
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
Lamendola C; Abbasi F; Chu JW; Hutchinson H; Cain V; Leary E; McLaughlin T; Stein E; Reaven G
Am J Cardiol; 2005 Jan; 95(2):189-93. PubMed ID: 15642550
[TBL] [Abstract][Full Text] [Related]
10. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia.
Pirro M; Schillaci G; Mannarino MR; Savarese G; Vaudo G; Siepi D; Paltriccia R; Mannarino E
Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):436-41. PubMed ID: 17134956
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice.
Li W; Asagami T; Matsushita H; Lee KH; Tsao PS
J Pharmacol Exp Ther; 2005 May; 313(2):557-62. PubMed ID: 15665143
[TBL] [Abstract][Full Text] [Related]
12. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia.
ter Avest E; Abbink EJ; de Graaf J; Tack CJ; Stalenhoef AF
Eur J Clin Invest; 2005 Sep; 35(9):558-64. PubMed ID: 16128862
[TBL] [Abstract][Full Text] [Related]
13. Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy.
Shepherd J; Packard C; Littlejohn TW; Walker J; Stein EA; Smith K; Kallend D; Blasetto JW
Curr Med Res Opin; 2004 Oct; 20(10):1571-8. PubMed ID: 15462690
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.
Kapur NK
Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):161-75. PubMed ID: 17338662
[TBL] [Abstract][Full Text] [Related]
15. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
[TBL] [Abstract][Full Text] [Related]
16. Effect of rosuvastatin on methionine-induced hyperhomocysteinaemia and haematological changes in rats.
Nigam GK; Ansari MN; Bhandari U
Basic Clin Pharmacol Toxicol; 2008 Sep; 103(3):287-92. PubMed ID: 18684217
[TBL] [Abstract][Full Text] [Related]
17. LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet.
Hu C; Dandapat A; Sun L; Chen J; Marwali MR; Romeo F; Sawamura T; Mehta JL
Cardiovasc Res; 2008 Jul; 79(2):287-93. PubMed ID: 18453637
[TBL] [Abstract][Full Text] [Related]
18. Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques.
He L; Game BA; Nareika A; Garvey WT; Huang Y
J Cardiovasc Pharmacol; 2006 Nov; 48(5):212-22. PubMed ID: 17110803
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?
Efthimiadis A
Angiology; 2008; 59(2 Suppl):62S-4S. PubMed ID: 18628276
[TBL] [Abstract][Full Text] [Related]
20. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice.
Kuzuya M; Nakamura K; Sasaki T; Cheng XW; Itohara S; Iguchi A
Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1120-5. PubMed ID: 16556856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
